Current Report Filing (8-k)
December 20 2017 - 5:02PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of report (date of earliest event reported): December 20, 2017
OWC
Pharmaceutical Research Corp.
(Exact Name of Registrant as Specified in its Charter)
Commission
File No.: 0-54856
Delaware
|
|
98-0573566
|
(State
of Incorporation)
|
|
(I.R.S.
Employer Identification No.)
|
|
|
|
30
Shacham Street. P.O.B. 8324 Petach Tikva, Israel
|
|
4918103
|
(Address
of Principal Executive Offices)
|
|
(ZIP
Code)
|
Registrant’s
Telephone Number, including area code: 972 (0) 3-758-2657
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item
8.01. Other Events.
OWC
Pharmaceutical Research Corp. (the “Registrant”), is filing with this Form 8-K, a Press Release, a copy of which is
attached hereto as Exhibit 99.1 and is dated and will be published tomorrow, December 21, 2017. The Registrant’s Press Release
announces that the Registrant received a new permit from the Israel Medical Cannabis Agency [MCA] to proceed with the safety study
of their oral disintegrating tablet. The study protocol will be submitted to the Institutional Review Board [IRB] at a leading
Israeli academic hospital in the coming weeks. The study is scheduled to start in Q2 2018.
Item
9.01 Financial Statements and Exhibits.
(a)
The following documents are filed as exhibits to this report on Form 8-K or incorporated by reference herein. Any document incorporated
by reference is identified by a parenthetical reference to the SEC filing that included such document.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
OWC
Pharmaceutical Research Corp.
|
|
|
|
|
By:
|
/s/
Mordechai Bignitz
|
|
Name:
|
Mordechai
Bignitz
|
|
Title:
|
Chief
Executive Officer
|
|
Date:
December 20, 2017
OWC Pharmaceuticals Rese... (CE) (USOTC:OWCP)
Historical Stock Chart
From Aug 2024 to Sep 2024
OWC Pharmaceuticals Rese... (CE) (USOTC:OWCP)
Historical Stock Chart
From Sep 2023 to Sep 2024